Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922567 | 0.88 | DRD2 (0.42) | KCNH2DRD2MEN1KMT2APER2 | |
| SCHEMBL6924575 | 0.87 | DRD2 (0.42) | KCNH2DRD2MEN1KMT2APER2 | |
| SCHEMBL6929465 | 0.87 | HTR1A (0.41) | KCNH2DRD2DRD3PTGDR2MEN1 | |
| SCHEMBL6928917 | 0.86 | DRD2 (0.42) | KCNH2DRD2MEN1KMT2APER2 | |
| SCHEMBL6928602 | 0.84 | PER2 (0.46) | DRD2PTGDR2PER2 | |
| SCHEMBL6922897 | 0.84 | PTGDR (0.39) | KCNH2PTGDR2PTGDRPER2 | |
| SCHEMBL6928509 | 0.82 | PTGDR2 (0.42) | KCNH2DRD2DRD3PTGDR2PER2 | |
| SCHEMBL6928221 | 0.81 | DRD2 (0.41) | KCNH2DRD2MEN1KMT2APER2 | |
| SCHEMBL6927068 | 0.76 | DRD2 (0.41) | DRD2PTGDR2MEN1KMT2APER2 | |
| SCHEMBL6928224 | 0.76 | PRMT5 (0.39) | KCNH2DRD2DRD3PTGDR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | H. LUNDBECK A/S (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6514993-B1 | Useful in the treatment of certain psychic and neurologic disorders | H. LUNDBECK A/S (DK) | 2003-02-04 | — | — | US | disclosed |
| EP-0770066-B1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2000-05-17 | — | — | EP | disclosed |
| EP-0770066-A1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995033729-A1 | SEROTONIN 5-HT1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | HTR5A, HTR2C, HTR1D | KCNH2 233/4885DRD2 7/4885DRD3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.